Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a new lecithinized coal tar formulation did not stain different types of mammalian hair, suggesting it may be promising for treating scalp psoriasis without the drawback of staining.

In this case study, medical management with trilostane improved clinical signs and normalized serum chemistry in a dog diagnosed with adrenal-dependent hyperadrenocorticism over 80 weeks of treatment.

This study developed a new method to analyze Cantú syndrome mutations in KATP channels, finding that while Kir6.1 mutations increase sensitivity to potassium channel openers, SUR2B mutations show reduced sensitivity, but both result in marked hyperpolarization compared to wild-type channels under basal conditions.

This study found that sodium selenite induced both subacute and chronic selenosis in cow calves, significantly affecting specific haematological parameters, with more pronounced alterations observed in chronic toxicity.

In this study, patients with mild to moderate scalp seborrheic dermatitis experienced greater improvements in severity scores and quality of life with Lulican™ shampoo compared to Ketoconazole over four weeks, with similar safety profiles but better tolerability and cosmetic acceptability for LulicanTM.

In this study, patients with active lymphocytic cicatricial alopecia showed significant improvement using a three-stage treatment regimen involving Tofacitinib, Apremilast, and Crisaborole, with 93.5% experiencing marked improvement and only three mild adverse events reported.

In a double-blind clinical trial, this study found that a gel containing chitosan-coated spironolactone nanoparticles effectively reduced acne lesions over 8 weeks without adverse skin effects, suggesting potential for enhanced acne treatment through targeted skin delivery.

This study reported that a solid lipid nanoparticle-based gel formulation, specifically optimized for psoriasis, improved drug loading capacity and release properties using high-pressure homogenization, suggesting its potential efficacy as a topical treatment.

This study found that silver nanoparticles synthesized using Lens culinaris extract exhibited potent anticancer activity against MCF-7, HCT-116, and HepG2 cell lines and significant antimicrobial effects against Klebsiella pneumoniae and Acinetobacter baumannii.

This study found that nanostructured lipid carriers could serve as a promising vehicle for topical Acitretin delivery in psoriasis treatment, potentially reducing oral side effects and enhancing patient compliance.

Repaglinide-loaded liponiosomal hybrids improve blood sugar control and insulin release better than regular Repaglinide.

The researchers reported that a child with epilepsy developed encephalopathy after an asymptomatic COVID-19 infection, confirmed by clinical and laboratory assessments showing post-COVID19 effects.

In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.

This study suggests that spironolactone-loaded nanostructured lipid carriers could enhance follicular delivery and offer a more localized treatment for androgenic alopecia, potentially reducing systemic side effects.

In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.

This study found that the combination of letrozole and quercetin loaded in spanlastics showed enhanced cytotoxicity and other anticancer effects against MCF-7 breast cancer cells compared to individual treatments.

This report details two cases of Lichen spinulosus in the submental area, treated effectively and safely with topical tacalcitol cream.

This chapter highlights various commercial and open-source light sheet microscopy systems, detailing their rapid evolution and integration of multimodal technologies, with a focus on the ZEISS Lightsheet Z.1 system's advanced design for direct imaging and specialized sample mounting.

This article discusses revised SLE classification criteria by the SLICC and reports no new research results.

This trial explores whether spironolactone is more effective than cyclines for treating moderate acne in adult women, providing a potential alternative amidst concerns over antibiotic resistance.

This review discusses home-use laser and light skin devices for various dermatological purposes and reports no new clinical findings; the authors highlight the need for dermatologists to evaluate these devices' clinical value.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.

This study identified "HTLV-1-associated lichenoid dermatitis" as a skin condition in HTLV-1-infected individuals, characterized by reactive eruptions associated with increased immunity toward infected CD4+ T cells.

This review discusses the role of latanoprost in hair growth but reports no clinical results; the authors suggest further research to determine its efficacy and optimal treatment regimen.

This study observed that infrared light therapy, alone or combined with hyaluronic acid and calcium hydroxylapatite, effectively improved skin laxity with high patient satisfaction and minimal adverse effects among women aged 37 to 68.

This study found that in a mouse model of Focal Dermal Hypoplasia, treatment with lithium carbonate improved skin disease symptoms compared to controls, though disease severity varied and posed interpretation challenges.

This audit of ritlecitinib prescribing for severe alopecia areata found that regional practices largely followed national guidelines but highlighted the need for better psychological assessments and more consistent use of SALT scoring to inform treatment continuation decisions after 36 weeks.

In this report, NICE has approved ritlecitinib, an oral kinase inhibitor, as the first recommended treatment for severe alopecia areata in individuals aged 12 and older.